Product development update

Futura Medical PLC 12 August 2005 Press release 12 August 2005 Futura Medical Plc Female Lubrication Device - Product development update Futura Medical plc ('Futura' or 'the Company'), the AIM-listed pharmaceutical and medical device group that develops innovative products for the sexual healthcare market, today announced it has completed its clinical assessment programme for the Female Lubrication Device ('FLD500'). Following a review of all the clinical data by Futura's panel of consultants and supported by preliminary feedback from an EU competent authority no further clinical work is planned prior to the submission of the dossier for FLD500 for regulatory approval in the European Union. Work is continuing to finalise the product, develop the manufacturing process and complete remaining supportive data including stability in order to submit the dossier. James Barder, Chief Executive of Futura Medical, said: 'This is further good news for FLD500 and its progress to market, following SSL's exercise of its option for global distribution rights for the product. The present clinical assessment of FLD500 is considered sufficient for regulatory requirements and we avoid the expense and time associated with conducting a further clinical study.' In early July Futura announced that SSL International plc ('SSL'), the consumer healthcare brands company and manufacturer and distributor of DurexTM, the world's biggest-selling branded condom, had exercised its option for the global marketing and distribution rights for FLD500. For further information: Futura Medical plc James Barder, Chief Executive Tel: +44 (0) 1483 845 670 mail to: james.barder@futuramedical.co.uk www.futuramedical.co.uk Media enquiries: Abchurch Samantha Robbins Tel: +44 (0) 20 7398 7700 mailto: samantha.robbins@abchurch-group.com www.abchurch-group.com Notes to Editors: Futura Medical Futura Medical is an AIM-listed pharmaceutical drug and medical device group developing innovative products for sexual health. The Company is developing a portfolio of products with the intention of licensing their manufacture and distribution to major pharmaceutical and healthcare groups. Several agreements have been signed. Futura's primary focus is on Over the Counter ('OTC') products with particular appeal to men and women who are reluctant to discuss potentially embarrassing sexual matters with their doctors. The Company has three products in development and is in discussions to expand the pipeline. CSD500 is a latex condom incorporating an erectogenic compound within its teat a gel to help healthy men maintain an erection throughout intercourse, thereby reducing the likelihood of condom slippage. An exclusive agreement for worldwide distribution has been signed with SSL International plc, the maker of DurexTM. FLD500, aimed primarily at female partners of male condom users, will help women maintain lubrication during intercourse, thereby reducing the risk of condom failure. SSL International plc has exclusive worldwide distribution rights. In trials, MED2002, a locally applied gel for erectile dysfunction ('ED'), has shown dramatically improved dermal absorption rates and a dose-ranging study is currently being conducted prior to commencement of a Phase III study. Futura has entered into exclusive discussions with a major global pharmaceutical group for the worldwide development and marketing of MED2002. A trial to assess the safety of MED2002 in angina patients has already been successfully completed. Subject to regulatory approval the Company intends to recruit men suffering from ED with mild to moderate angina into the Phase III trial. Normal medications taken by angina patients prevent the use of available ED treatments such as ViagraTM, CialisTM and LevitraTM. www.futuramedical.co.uk This information is provided by RNS The company news service from the London Stock Exchange